N

National Institutes of Health | National Institutes of Health Clinical Center | Critical Care Medicine Department

Research site
(Unclaimed)
Location
2C137A MSC 1662, Bethesda, Maryland, United States of America

Site insights

Top conditions

Top treatments

Androgen
Bosentan
Leniolisib
AZD6244
ONC206
sirolimus
AJ201
cyclophosphamide
Thalidomide
STAR0602

Parent organization

This site is a part of National Institutes of Health

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 43 total trials

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent...

Enrolling
Abdominal Neoplasm
Neoplasms by Site
Drug: STAR0602

This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201...

Active, not recruiting
Spinal and Bulbar Muscular Atrophy
Kennedy's Disease
Drug: Placebo
Drug: AJ201

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting
Prader-Willi Syndrome
Drug: DCCR

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic...

Enrolling
APDS
Drug: Leniolisib

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic...

Active, not recruiting
APDS
Drug: Leniolisib

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establi...

Enrolling
Glioblastoma
Glial Tumor
Drug: ONC206

Trial sponsors

National Cancer Institute (NCI) logo
Actelion Pharmaceuticals logo
Boston Children's Hospital logo
Emory University logo
M
National Institute of Allergy and Infectious Diseases (NIAID) logo
National Institutes of Health (NIH) logo
P
The University of Texas System (UT) logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems